{"id":"hyd","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Dizziness"},{"rate":"20-30","effect":"Drowsiness"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Dependence/addiction risk"}]},"_chembl":{"chemblId":"CHEMBL3527202","moleculeType":"Small molecule","molecularWeight":"224.24"},"patents":[],"_fixedAt":"2026-03-30T16:47:34.082742","_dailymed":{"setId":"01c04bad-3905-4776-b936-7b48ee6699df","title":"GOOD NEIGHBOR PHARMACY CHILDRENS ALLERGY (DIPHENHYDRAMINE HYDROCHLORIDE) SOLUTION [PREFERRED PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrocodone activates mu opioid receptors throughout the brain and spinal cord, reducing the perception of pain and suppressing cough reflex signals. It is a semi-synthetic opioid derived from codeine and is typically formulated in combination with acetaminophen or ibuprofen for enhanced analgesic effect.","oneSentence":"Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and cough suppression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:33:52.306Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to moderately severe pain"},{"name":"Cough suppression"}]},"_fixedFields":["generics(14)","patents(0)"],"patentStatus":"Off-patent — no active Orange Book patents","trialDetails":[{"nctId":"NCT06456346","phase":"PHASE3","title":"Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-16","conditions":"Essential Thrombocythemia","enrollment":300},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT06093672","phase":"PHASE3","title":"Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera","status":"RECRUITING","sponsor":"Italfarmaco","startDate":"2024-03-26","conditions":"Polycythemia Vera","enrollment":220},{"nctId":"NCT06871410","phase":"PHASE1","title":"Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-02","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":"Intracranial Meningioma","enrollment":153},{"nctId":"NCT07488520","phase":"PHASE4","title":"Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire","status":"NOT_YET_RECRUITING","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2026-04","conditions":"Sickle Cell Disease (SCD)","enrollment":120},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT06930352","phase":"PHASE2","title":"Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy","status":"NOT_YET_RECRUITING","sponsor":"Uma Borate","startDate":"2026-04-10","conditions":"Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT05853458","phase":"PHASE4","title":"Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-28","conditions":"Polycythemia Vera","enrollment":76},{"nctId":"NCT06063317","phase":"PHASE1","title":"A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2023-10-02","conditions":"Solid Tumor, Adult","enrollment":25},{"nctId":"NCT06526117","phase":"PHASE4","title":"Stroke Prevention in Nigeria 2 Trial","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2024-08-05","conditions":"Sickle Cell Disease, Stroke","enrollment":220},{"nctId":"NCT06923111","phase":"","title":"PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]","status":"RECRUITING","sponsor":"Nova Laboratories Limited","startDate":"2025-06-09","conditions":"Sickle Cell Disease","enrollment":180},{"nctId":"NCT07033598","phase":"PHASE2","title":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Theradex","startDate":"2026-01-01","conditions":"Leukemia, Myelomonocytic, Chronic","enrollment":66},{"nctId":"NCT05526924","phase":"PHASE1","title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-03-07","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma","enrollment":30},{"nctId":"NCT07232290","phase":"PHASE2","title":"Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2025-09-23","conditions":"Polycythemia Vera (PV)","enrollment":60},{"nctId":"NCT03165734","phase":"PHASE3","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-06-26","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":399},{"nctId":"NCT03974217","phase":"PHASE1","title":"Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-08-01","conditions":"Leukemia","enrollment":13},{"nctId":"NCT06979492","phase":"PHASE4","title":"Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-04","conditions":"Sickle Cell Disease, Pregnancy Related","enrollment":50},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT03708731","phase":"","title":"Exploring Adherence Monitoring in Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-03-12","conditions":"Sickle Cell Disease","enrollment":36},{"nctId":"NCT07116772","phase":"","title":"Serial Assessment of Fertility Experiences","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-07-10","conditions":"Sickle Cell Anemia","enrollment":250},{"nctId":"NCT03814746","phase":"PHASE3","title":"Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-07-26","conditions":"Sickle Cell Disease (SCD)","enrollment":255},{"nctId":"NCT06786234","phase":"PHASE1","title":"A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia","status":"RECRUITING","sponsor":"Step Pharma, SAS","startDate":"2025-06-18","conditions":"Essential Thrombocythaemia","enrollment":20},{"nctId":"NCT04217356","phase":"","title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-05","conditions":"Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer","enrollment":90},{"nctId":"NCT03500731","phase":"PHASE1, PHASE2","title":"Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-04-19","conditions":"Idiopathic Pulmonary Fibrosis, Emphysema or COPD","enrollment":8},{"nctId":"NCT04528355","phase":"","title":"Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2020-08-20","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":50},{"nctId":"NCT05451940","phase":"PHASE1, PHASE2","title":"Hydroxyurea and EPO in Sickle Cell Disease","status":"COMPLETED","sponsor":"Julia Xu","startDate":"2023-05-25","conditions":"Anemia, Sickle Cell, Sickle Cell Disease","enrollment":17},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT05405114","phase":"PHASE2","title":"Research Study Investigating How Well NDec Works in People With Sickle Cell Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-07-07","conditions":"Sickle Cell Disease","enrollment":96},{"nctId":"NCT07292259","phase":"PHASE2","title":"Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia","status":"RECRUITING","sponsor":"Pakistan Blood and Marrow Transplant (PBMT) Group","startDate":"2024-01-01","conditions":"Transfusion Dependent Beta Thalassemia","enrollment":150},{"nctId":"NCT05020652","phase":"PHASE2","title":"A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-11-11","conditions":"Moderate and High Risk Myelofibrosis","enrollment":107},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT01962415","phase":"PHASE2","title":"Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2014-02-04","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":100},{"nctId":"NCT04576156","phase":"PHASE3","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geron Corporation","startDate":"2021-04-12","conditions":"Myelofibrosis","enrollment":327},{"nctId":"NCT05398809","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-18","conditions":"Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata","enrollment":70},{"nctId":"NCT01933932","phase":"PHASE3","title":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2013-09-25","conditions":"Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV","enrollment":510},{"nctId":"NCT06552429","phase":"PHASE2","title":"Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2024-08-29","conditions":"Essential Thrombocythemia","enrollment":27},{"nctId":"NCT05213572","phase":"","title":"Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-03-24","conditions":"Mortality in Sickle Cell, Sickle Cell Cardiopulmonary Complications, Sickle Cell Organ Damage","enrollment":200},{"nctId":"NCT00726232","phase":"PHASE2","title":"Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2008-08-20","conditions":"Myeloproliferative Neoplasm (MPN)","enrollment":73},{"nctId":"NCT03474965","phase":"PHASE2","title":"Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-01","conditions":"Sickle Cell Disease (SCD)","enrollment":117},{"nctId":"NCT02158858","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2014-07-16","conditions":"Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":336},{"nctId":"NCT07210450","phase":"PHASE2, PHASE3","title":"Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2023-08-15","conditions":"Pulmonary Artery Pressure, Thalassemia, Non-transfusion Dependent Thalassemia","enrollment":8},{"nctId":"NCT04562870","phase":"PHASE2","title":"A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2021-03-17","conditions":"Myelofibrosis","enrollment":112},{"nctId":"NCT05249452","phase":"","title":"Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2018-03-08","conditions":"Sickle Cell Disease","enrollment":20},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT07170592","phase":"PHASE1","title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Bionoxx Inc.","startDate":"2025-12","conditions":"Treatment-Refractory Solid Tumors","enrollment":24},{"nctId":"NCT04662931","phase":"PHASE4","title":"An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-14","conditions":"Sickle Cell Disease (SCD)","enrollment":140},{"nctId":"NCT07190833","phase":"PHASE1","title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)","status":"NOT_YET_RECRUITING","sponsor":"Bionoxx Inc.","startDate":"2025-11","conditions":"Treatment-Refractory Solid Tumors","enrollment":27},{"nctId":"NCT05953584","phase":"PHASE2","title":"A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke","status":"RECRUITING","sponsor":"Forma Therapeutics, Inc.","startDate":"2023-06-20","conditions":"Sickle Cell Disease","enrollment":27},{"nctId":"NCT06578507","phase":"PHASE2","title":"Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"Theravia","startDate":"2025-01-21","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT07177300","phase":"PHASE4","title":"Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-12-19","conditions":"Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)","enrollment":50},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT04808778","phase":"","title":"Stroke Prevention in Young Adults With Sickle Cell Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-05-17","conditions":"Sickle Cell Disease, Sickle Cell Anemia, Stroke, Ischemic","enrollment":250},{"nctId":"NCT05548062","phase":"","title":"Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-02","conditions":"Polycythemia Vera","enrollment":242},{"nctId":"NCT02769845","phase":"NA","title":"SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2016-03-16","conditions":"Sickle Cell Anemia","enrollment":283},{"nctId":"NCT02556099","phase":"PHASE2","title":"EXTEND EXpanding Treatment for Existing Neurological Disease","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-08","conditions":"Sickle Cell Anemia","enrollment":43},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT04285086","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2020-08-25","conditions":"Essential Thrombocythemia","enrollment":174},{"nctId":"NCT03653338","phase":"PHASE1, PHASE2","title":"T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-08-02","conditions":"Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia","enrollment":5},{"nctId":"NCT01461837","phase":"PHASE2","title":"Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2012-01","conditions":"Sickle Cell Disease","enrollment":21},{"nctId":"NCT05485948","phase":"PHASE2","title":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2021-10-08","conditions":"Polycythemia Vera","enrollment":49},{"nctId":"NCT04093986","phase":"","title":"Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-12-22","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":200},{"nctId":"NCT03948867","phase":"PHASE2","title":"Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)","status":"ENROLLING_BY_INVITATION","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-04-24","conditions":"Sickle Cell Anemia in Children","enrollment":202},{"nctId":"NCT02286154","phase":"NA","title":"Therapeutic Response Evaluation and Adherence Trial (TREAT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-10","conditions":"Anemia, Sickle Cell","enrollment":150},{"nctId":"NCT07066072","phase":"NA","title":"The Radiofrequency Therapy in Management of Sickle Cell Disease Chronic Pain RCT Tested the Effect of TECAR Therapy on Sickle Cell Disease Chronic Pain.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-12-01","conditions":"the Use of Radiofrequency Ablation in Form of TECAR(Capacitive and Resistive Transfer Energy) in Chronic Pain of Sickle Cell Disease Patients","enrollment":170},{"nctId":"NCT06199557","phase":"PHASE1, PHASE2","title":"A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2024-05-23","conditions":"Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult","enrollment":48},{"nctId":"NCT03789591","phase":"PHASE3","title":"Hydroxyurea Optimization Through Precision Study","status":"COMPLETED","sponsor":"Lifespan","startDate":"2019-01-17","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":104},{"nctId":"NCT03442114","phase":"NA","title":"Shared-Decision Making for Hydroxyurea","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-07-12","conditions":"Sickle Cell Anemia, Children, Only","enrollment":176},{"nctId":"NCT04687176","phase":"PHASE2","title":"Frontline Oral Arsenic Trioxide for APL","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT02577926","phase":"PHASE2","title":"The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"RWTH Aachen University","startDate":"2015-10","conditions":"Polycythemia Vera (PV), Essential Thrombocythemia (ET)","enrollment":207},{"nctId":"NCT06005324","phase":"PHASE1","title":"Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-12-18","conditions":"HPV-Negative Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT06490601","phase":"PHASE2","title":"Long Term Beta Thalassemia Treatment: Findings From The Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2022-04-01","conditions":"Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies","enrollment":30},{"nctId":"NCT02577406","phase":"PHASE3","title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-12-30","conditions":"Leukemia, Myeloid, Isocitrate Dehydrogenase","enrollment":319},{"nctId":"NCT06171217","phase":"PHASE2","title":"Realizing Effectiveness Across Continents With Hydroxyurea","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-10-27","conditions":"Sickle Cell Disease, Children","enrollment":810},{"nctId":"NCT03806452","phase":"PHASE2","title":"SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)","status":"COMPLETED","sponsor":"Theravia","startDate":"2019-05-28","conditions":"Sickle Cell Disease","enrollment":86},{"nctId":"NCT01966731","phase":"PHASE1, PHASE2","title":"Realizing Effectiveness Across Continents With Hydroxyurea (REACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-06","conditions":"Sickle Cell Disease","enrollment":635},{"nctId":"NCT03944915","phase":"PHASE2","title":"De-Escalation Therapy for Human Papillomavirus Negative Disease","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2019-08-26","conditions":"Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck","enrollment":35},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT04329325","phase":"PHASE2","title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-30","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive","enrollment":17},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT04750707","phase":"PHASE3","title":"Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )","status":"COMPLETED","sponsor":"Global Health Uganda LTD","startDate":"2021-03-09","conditions":"Sickle Cell Anemia in Children","enrollment":270},{"nctId":"NCT01499888","phase":"PHASE1, PHASE2","title":"Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2011-11-11","conditions":"Sickle Cell Disease","enrollment":45},{"nctId":"NCT05285917","phase":"PHASE3","title":"Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa","status":"RECRUITING","sponsor":"Brown University","startDate":"2023-11-15","conditions":"Sickle Cell Anemia in Children, Sickle Cell Disease","enrollment":400},{"nctId":"NCT06264700","phase":"NA","title":"Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2024-07-11","conditions":"Sickle Cell Disease","enrollment":60},{"nctId":"NCT06881056","phase":"NA","title":"Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2024-07-17","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":90},{"nctId":"NCT01420783","phase":"PHASE2","title":"Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"Hematopoietic Neoplasm","enrollment":81},{"nctId":"NCT04126681","phase":"PHASE2","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-10-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":144},{"nctId":"NCT04539678","phase":"","title":"SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2019-05-21","conditions":"Thrombotic Patients, Diagnosis of Myeloproliferative Neoplasia, Impact of Treatment With Cytoreducing Agent","enrollment":253},{"nctId":"NCT05662098","phase":"EARLY_PHASE1","title":"Alternative Dosing And Prevention of Transfusions (ADAPT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2022-06-16","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT06464458","phase":"NA","title":"Optimizing the Management of Sickle Cell Patients on Hydroxyurea: The Value of Therapeutic Pharmacological Monitoring","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-02-08","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT06318143","phase":"NA","title":"mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria","status":"RECRUITING","sponsor":"New York University","startDate":"2024-07-01","conditions":"Sickle Cell Disease","enrollment":900},{"nctId":"NCT06761560","phase":"PHASE2, PHASE3","title":"Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia","status":"NOT_YET_RECRUITING","sponsor":"Yves Pastore","startDate":"2025-01-15","conditions":"Sickle Cell Disease (SCD)","enrollment":29},{"nctId":"NCT04691323","phase":"NA","title":"The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2021-03-02","conditions":"Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia","enrollment":68},{"nctId":"NCT02165007","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2015-01","conditions":"Sickle Cell-thalassemia Disease, Thalassemia","enrollment":7},{"nctId":"NCT06606886","phase":"PHASE4","title":"Effects of Hydroxyurea and Metformin in Transfusion Dependent Beta-Thalassemia","status":"RECRUITING","sponsor":"Bahria University","startDate":"2024-09-16","conditions":"Transfusion Dependent Beta-thalassemia","enrollment":96},{"nctId":"NCT04688411","phase":"NA","title":"An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2020-09-28","conditions":"Sickle Cell Disease, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia","enrollment":40},{"nctId":"NCT04116502","phase":"PHASE3","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-10-25","conditions":"Polycythemia Vera","enrollment":586}],"_emaApprovals":[],"_faersSignals":[],"_patentsChecked":true,"_approvalHistory":[],"publicationCount":1072,"genericManufacturers":14,"_genericFilersChecked":true,"genericManufacturerList":["Able","Bel Mar","Cenci","Colgate","Fera Pharms","Fougera Pharms","Imperium","Ingram Pharm","Legacy Pharma","Parke Davis","Purepac Pharm","Sun Pharma Canada","Watson Labs","X Gen Pharms"],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"HYD","genericName":"HYD","companyName":"Purdue Pharma LP","companyId":"purdue-pharma-lp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and cough suppression. Used for Moderate to moderately severe pain, Cough suppression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}